keyword
MENU ▼
Read by QxMD icon Read
search

4CmenB

keyword
https://www.readbyqxmd.com/read/29410413/crystal-structure-reveals-vaccine-elicited-bactericidal-human-antibody-targeting-a-conserved-epitope-on-meningococcal-fhbp
#1
Jacinto López-Sagaseta, Peter T Beernink, Federica Bianchi, Laura Santini, Elisabetta Frigimelica, Alexander H Lucas, Mariagrazia Pizza, Matthew J Bottomley
Data obtained recently in the United Kingdom following a nationwide infant immunization program against serogroup B Neisseria meningitidis (MenB) reported >80% 4CMenB vaccine-mediated protection. Factor H-binding protein (fHbp) is a meningococcal virulence factor and a component of two new MenB vaccines. Here, we investigated the structural bases underlying the fHbp-dependent protective antibody response in humans, which might inform future antigen design efforts. We present the co-crystal structure of a human antibody Fab targeting fHbp...
February 6, 2018: Nature Communications
https://www.readbyqxmd.com/read/29374626/4cmenb-and-post-immunisation-fever-an-emerging-hot-topic
#2
Maya Lamoudi, Faye Baxter, Amarpal Bilkhu, Claire Hathorn
No abstract text is available yet for this article.
January 27, 2018: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/29371070/immunogenicity-and-safety-of-the-multicomponent-meningococcal-b-vaccine-4cmenb-in-children-and-adolescents-a-systematic-review-and-meta-analysis
#3
Maria Elena Flacco, Lamberto Manzoli, Annalisa Rosso, Carolina Marzuillo, Mario Bergamini, Armando Stefanati, Rosario Cultrera, Paolo Villari, Walter Ricciardi, John P A Ioannidis, Despina G Contopoulos-Ioannidis
BACKGROUND: The multicomponent meningococcal serogroup B vaccine (4CMenB) has been licensed in more than 35 countries. However, uncertainties remain about the lowest number of doses required to induce satisfactory, persistent immune responses. We did a systematic review and meta-analysis to provide quantitative estimates for the immunogenicity, persistence of immunogenicity, and safety of 4CMenB vaccine in children and adolescents. METHODS: For this systematic review and meta-analyses (proportion, head to head, and network), we searched MEDLINE, Scopus, Embase, and ClinicalTrials...
January 19, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29371069/growing-evidence-supports-4cmenb-effectiveness
#4
Shamez N Ladhani, Ray Borrow, Nick J Andrews
No abstract text is available yet for this article.
January 19, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29337653/safety-and-immunogenicity-of-a-meningococcal-b-recombinant-vaccine-when-administered-with-routine-vaccines-to-healthy-infants-in-taiwan-a-phase-3-open-label-randomized-study
#5
Nan-Chang Chiu, Li-Min Huang, Arnold Willemsen, Chiranjiwi Bhusal, Ashwani Kumar Arora, Zenaida Reynoso Mojares, Daniela Toneatto
Neisseria meningitidis is associated with high mortality and morbidity in infants and children worldwide. This phase 3 study (NCT02173704) evaluated safety and immunogenicity of a 4-component serogroup B recombinant meningococcal vaccine (4CMenB) co-administered with routine vaccines in Taiwanese infants. In total, 225 healthy infants were randomized (2:1) to receive 4CMenB and routine vaccines (4CMenB+Routine) or routine vaccines only (Routine group) at 2, 4, 6 and 12 months of age. Routine vaccines were diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b, 13-valent pneumococcal, hepatitis B, measles-mumps-rubella and varicella vaccines...
January 16, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29329168/immune-responses-to-booster-vaccination-with-meningococcal-abcwy-vaccine-following-primary-vaccination-with-either-investigational-or-licensed-vaccines-a-phase-2-randomized-study
#6
Leszek Szenborn, Stan L Block, Teresa Jackowska, Ryszard Konior, Diego DʼAgostino, Igor Smolenov, Daniela Toneatto, Jo Anne Welsch
BACKGROUND: Current meningococcal prime-boost vaccination schedules include separate vaccines for serogroups ACWY and B. An investigational combined serogroups ABCWY vaccine (MenABCWY) was developed to protect against clinically important Neisseria meningitidis serogroups. METHODS: In this phase 2, randomized, observer-blind, extension study (NCT01272180), participants aged 10-25 years received 1 booster dose of MenABCWY vaccine at 24 months (M) post-primary series of either MenABCWY (2 doses), 4CMenB (2 doses) or MenACWY-CRM vaccine (1 dose)...
January 11, 2018: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29246475/estimating-primary-care-attendance-rates-for-fever-in-infants-after-meningococcal-b-vaccination-in-england-using-national-syndromic-surveillance-data
#7
Sally Harcourt, Roger A Morbey, Chris Bates, Helen Carter, Shamez N Ladhani, Simon de Lusignan, Gillian E Smith, Alex J Elliot
BACKGROUND: In September 2015, the United Kingdom became the first country to introduce the multicomponent group B meningococcal vaccine (4CMenB) into a national infant immunisation programme. In early clinical trials 51-61% of infants developed a fever when 4CMenB was administered with other routine vaccines. Whilst administration of prophylactic paracetamol is advised, up to 3% of parents may seek medical advice for fever following vaccination. We used research-level general practitioner consultations to identify any increase in attendances for all-cause fever in vaccine-eligible infants following 4CMenB introduction in England...
December 12, 2017: Vaccine
https://www.readbyqxmd.com/read/29038320/persistence-of-immunity-after-vaccination-with-a-capsular-group-b-meningococcal-vaccine-in-3-different-toddler-schedules
#8
RANDOMIZED CONTROLLED TRIAL
Manish Sadarangani, Tim Sell, Mildred A Iro, Matthew D Snape, Merryn Voysey, Adam Finn, Paul T Heath, Gianni Bona, Susanna Esposito, Javier Diez-Domingo, Roman Prymula, Adefowope Odueyungbo, Daniela Toneatto, Andrew J Pollard
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12-23 months, with a booster dose 12-24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres in children up to 4 years of age after initial doses at 12-24 months, and immunogenicity of a booster dose at 48 months of age compared with vaccine-naive children. METHODS: Children previously immunized, as part of a randomized controlled trial, with 2 doses of 4CMenB vaccine at 12-24 months of age received a booster at 4 years of age...
October 16, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/28987549/potential-impact-of-the-4cmenb-vaccine-on-oropharyngeal-carriage-of-neisseria-meningitidis
#9
Raquel Abad, Verónica Medina, Maria Del Carmen Fariñas, Luis Martínez-Martínez, Stefania Bambini, A Dari, Duccio Medini, Mariagrazia Pizza, Julio A Vázquez
The analysis of the potential impact of the meningococcal vaccines in asymptomatic carriers has become one of the key aspects in the evaluation of new vaccines and of their impact on disease control. An important step in this direction is provided by the analysis of the sequence variability and surface-exposure of the 4CMenB (Bexsero®) vaccine antigens, as well as the cross-reactivity of vaccine induced antibodies, in isolates from healthy carriers. The Spanish Reference Laboratory, in collaboration with the University Hospital Marqués de Valdecilla in Santander (Spain), carried out a meningococcal carrier survey between May 2010 and April 2012 (population aged 4 to 19 years)...
October 5, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28931535/risk-of-hospitalisation-with-fever-following-menb-vaccination-self-controlled-case-series-analysis
#10
Heather Murdoch, Lynn Wallace, Jennifer Bishop, Chris Robertson, J Claire Cameron
OBJECTIVE: To investigate a possible association between fever admissions and 4 component Meningococcal B (4CMenB). DESIGN: 4CMenB is given at 8 and 16 weeks in the first year of life. Self-controlled case series using linked routinely collected healthcare data, where the risk period was the 3 days immediately following receipt of a vaccine dose. PATIENTS: Children aged under 1 year in Scotland preintroduction and postintroduction of 4CMenB vaccine (pre-September 2014 to August 2015 and post-September 2015 to June 2016)...
October 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28794096/an-increase-in-accident-and-emergency-presentations-for-adverse-events-following-immunisation-after-introduction-of-the-group-b-meningococcal-vaccine-an-observational-study
#11
Viveka Nainani, Ushma Galal, Jim Buttery, Matthew D Snape
OBJECTIVES: To determine whether the introduction of the capsular group B meningococcal vaccine (4CMenB) in the UK has increased presentations of infants to emergency departments with adverse events following immunisation (AEFI). PARTICIPANTS, DESIGN AND SETTING: A retrospective review of hospital records of infants aged 1-6 months presenting to Oxford University Hospitals NHS Trust's emergency departments from September 2013 to August 2016 with discharge diagnoses of vaccine reactions or non-specific conditions...
August 9, 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28637642/emergency-department-attendance-following-4-component-meningococcal-b-vaccination-in-infants
#12
Sarah Kapur, Thomas Bourke, Julie-Ann Maney, Paul Moriarty
INTRODUCTION: In September 2015, the UK became the first country in the world to introduce the 4-component meningococcal B vaccine(4CMenB) into the routine vaccine schedule for infants. 4CMenB is known to cause fever in infants. Infants presenting with fever, particularly those under 3 months, have a significant risk of serious bacterial infection(SBI). METHOD: Between September 2015 and January 2016, we performed a prospective audit of management of infants between 30 and 180 days attending the regional paediatric emergency department(ED) in Northern Ireland, within 4 days of receiving 4CMenB...
October 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28624305/durability-of-immunogenicity-and-strain-coverage-of-menbvac-a-meningococcal-vaccine-based-on-outer-membrane-vesicles-lessons-of-the-normandy-campaign
#13
Julien Sevestre, Eva Hong, Valérie Delbos, Aude Terrade, Eric Mallet, Ala-Eddine Deghmane, Ludovic Lemée, Muhamed-Kheir Taha, François Caron
OBJECTIVES: MenBvac® is an outer membrane vesicle (OMV)-based meningococcal vaccine. From 2006 to 2012, it was used to control a clonal B outbreak in Normandy (France). We aimed to analyse the durability of the response against the epidemic strain and coverage beyond the vaccine strain. These data should help to optimize the use of OMV-containing vaccines, such as the new 4CMenB/Bexsero® recombinant vaccine. METHODS: Serum bactericidal activity (SBA) was measured in two cohorts of children who received their first dose of MenBvac® at 1-5years of age and accepted to provide a blood sample either one or four years after a 2+1+1 schedule...
July 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28533054/reduced-schedules-of-4cmenb-vaccine-in-infants-and-catch-up-series-in-children-immunogenicity-and-safety-results-from-a-randomised-open-label-phase-3b-trial
#14
Federico Martinón-Torres, Marco Aurelio P Safadi, Alfonso Carmona Martinez, Pilar Infante Marquez, Juan Carlos Tejedor Torres, Lily Yin Weckx, Edson Duarte Moreira, Ilhem Mensi, Marco Calabresi, Daniela Toneatto
BACKGROUND: This study evaluated the immunogenicity and safety of a licensed meningococcal serogroup B vaccine (4CMenB) administered alone according to reduced schedules in infants or catch-up series in children. METHODS: In this open-label, multicentre, phase 3b study (NCT01339923), infants randomised 1:1:1 received 4CMenB: 2+1 doses at 3½-5-11months or 6-8-11months of age, 3+1 doses at ages 2½-3½-5-11months. Children aged 2-10years received 2 catch-up doses administered 2months apart...
June 16, 2017: Vaccine
https://www.readbyqxmd.com/read/28524748/an-unwanted-guest-neisseria-meningitidis-carriage-risk-for-invasive-disease-and-the-impact-of-vaccination-with-insight-on-italy-incidence
#15
Elena Gianchecchi, Giulia Piccini, Alessandro Torelli, Rino Rappuoli, Emanuele Montomoli
Invasive Meningococcal Disease (IMD) represents a potentially life-threatening condition caused by Neisseria meningitidis. The disease is characterized by a case fatality rate of 5-10% whereas serious clinical sequelae can develop in survivors within 12-24 h from the first symptoms. However, IMD infection only occurs rarely, in fact, most of the interactions established between N. meningitidis and the host are harmless, and an estimated 10% of the population asymptomatically carries the bacterium in the nasopharynx...
May 29, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28483197/corrigendum-to-persistence-of-bactericidal-antibodies-following-booster-vaccination-with-4cmenb-at-12-18-or-24months-and-immunogenicity-of-a-fifth-dose-administered-at-4years-of-age-a-phase-3-extension-to-a-randomised-controlled-trial-vaccine-35-2017-395-402
#16
Mildred A Iro, Matthew D Snape, Merryn Voysey, Sena Jawad, Adam Finn, Paul T Heath, Gianni Bona, Susanna Esposito, Javier Diez-Domingo, Roman Prymula, Adefowope Odueyungbo, Daniela Toneatto, Peter Dull, Andrew J Pollard
No abstract text is available yet for this article.
May 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28459837/predicted-strain-coverage-of-a-meningococcal-multicomponent-vaccine-4cmenb-in-portugal
#17
Maria João Simões, Célia Bettencourt, Rosita De Paola, Maria Giuliani, Mariagrazia Pizza, Monica Moschioni, Jorge Machado
OBJECTIVE: Although the incidence of meningococcal disease has been declining over the past decade in Portugal MenB meningococci is still an important cause of meningitis and sepsis. The aim of this study was to estimate the strain coverage of the 4CMenB vaccine in Portugal in order to support health policies for prevention and control of meningococcal disease. METHODS: Since 2002 the clinical and laboratory notification of meningococcal disease is mandatory in Portugal...
2017: PloS One
https://www.readbyqxmd.com/read/28375029/emerging-experience-with-meningococcal-serogroup-b-protein-vaccines
#18
REVIEW
Daniela Toneatto, Mariagrazia Pizza, Vega Masignani, Rino Rappuoli
The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary: The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials...
May 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28368526/discordant-effects-of-licensed-meningococcal-serogroup-b-vaccination-on-invasive-disease-and-nasal-colonization-in-a-humanized-mouse-model
#19
Carolyn M Buckwalter, Elissa G Currie, Raymond S W Tsang, Scott D Gray-Owen
Background.: The multicomponent meningococcal serogroup B vaccine (4CMenB) is an outer membrane vesicle and recombinant protein-based vaccine licensed to protect against serogroup B meningococcal disease. It remains unknown whether this vaccine will prevent carriage or transmission, key aspects in long-term vaccine success and disease eradication. Methods.: Using a "humanized" transgenic mouse model of nasal colonization, we took a systematic approach to estimate the potential for carriage prevention against antigenically diverse Neisseria meningitidis strains and to compare this protection to an invasive meningococcal disease challenge model...
May 15, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28366725/meningococcal-serogroup-b-strain-coverage-of-the-multicomponent-4cmenb-vaccine-with-corresponding-regional-distribution-and-clinical-characteristics-in-england-wales-and-northern-ireland-2007-08-and-2014-15-a-qualitative-and-quantitative-assessment
#20
Sydel R Parikh, Lynne Newbold, Stephanie Slater, Maria Stella, Monica Moschioni, Jay Lucidarme, Rosita De Paola, Maria Giuliani, Laura Serino, Stephen J Gray, Stephen A Clark, Jamie Findlow, Mariagrazia Pizza, Mary E Ramsay, Shamez N Ladhani, Ray Borrow
BACKGROUND: The UK introduced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisation programme in September, 2015. The Meningococcal Antigen Typing System (MATS) was used to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 in England and Wales (MATS coverage). We aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15, before 4CMenB introduction; compare strain coverage between 2007-08 and 2014-15; and investigate associations between MATS coverage, age, region, and disease outcomes...
July 2017: Lancet Infectious Diseases
keyword
keyword
61758
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"